doi:10.1530/eje.0.1460863 Lee S, Lee DY
Piggybacking off Cleveland Clinic's stance, the benefits of GLP-1 meds are likely to outweigh the risks for individuals with type 2 diabetes and obesity and NOT for vanity-driven users who solely want to quickly drop a few pounds for an upcoming event
Choi, T
Other gastrointestinal symptoms like semaglutide burping and general digestive discomfort tend to follow a similar pattern of onset and resolution
NICE recommends GLP-1 receptor agonist medications for adults with type 2 diabetes who haven't achieved adequate glycaemic control with lifestyle changes and other treatments, or for obesity management when specific BMI and comorbidity criteria are met
In addition, a large number of clinical studies have shown that GLP-/GIP dual agonists can reduce LFC, VAT, and body weight, and have an improvement effect on both NAFLD and NASH [131,132]